论文部分内容阅读
目的：研究PCNA、P16蛋白在卵巢癌中的表达及临床价值。方法：应用免疫组化法检测89份卵巢癌组织PCNA、P16蛋白的表达。结果：PCNA表达在上皮性，中、低分化以及晚期卵巢癌中的表达显著高于非上皮性，高分化及早期卵巢癌（P＜0．05），PCNA表达与残存癌灶大小、是否发生淋巴结转移无关（P＞0．05）。在晚期、残存癌灶≥2cm的卵巢癌中P16蛋白的表达明显低于早期、残存癌灶＜2cm者（P＜0．05）；P16蛋白表达与组织类型、组织分化、淋巴结有无转移无关（P＜0．05）。生存分析表明，PCNA、P16蛋白尚不能作为卵巢癌的独立预后因素。结论：肿瘤细胞的过度增殖在卵巢癌的发生、发展中起一定作用。P16蛋白表达的缺失与卵巢癌的进展有关。测定卵巢癌组织P16、PCNA的表达，对客观评价肿瘤的增殖状态，进行“个体化”治疗有指导价值。
Objective: To study the expression and clinical value of PCNA and P16 protein in ovarian cancer. Methods: The expressions of PCNA and P16 in 89 ovarian cancer tissues were detected by immunohistochemistry. Results: The expression of PCNA in epithelial, moderate and poorly differentiated as well as in advanced ovarian cancer was significantly higher than that in non-epithelial, well-differentiated and early-stage ovarian cancer (P <0.05). The expression of PCNA was correlated with the size of residual tumor and its occurrence Lymph node metastasis (P> 0.05). In advanced stage, the expression of P16 protein in ovarian cancer with residual cancer> 2 cm was significantly lower than that in early stage and residual cancer <2 cm (P <0.05). The expression of P16 protein was not related to the type of tissue, differentiation of tissues and metastasis of lymph nodes (P <0.05). Survival analysis showed that PCNA, P16 protein is not yet an independent prognostic factor for ovarian cancer. Conclusion: The over-proliferation of tumor cells plays a role in the occurrence and development of ovarian cancer. The lack of P16 protein expression is associated with the progression of ovarian cancer. Determination of ovarian cancer P16, PCNA expression, objective evaluation of tumor proliferation status, “individual” treatment has guiding value.